Trial Profile
A Multi-center, Randomized, Double Blind, Parallel Phase III Study to Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs KI 1107 (Primary) ; Rosuvastatin
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms ROMANTIC
- Sponsors Kuhnil Pharmaceutical Company
- 06 Dec 2017 Primary endpoint has been met. (Variation rate of Non HDL-C) as per results published in the Clinical Therapeutics
- 06 Dec 2017 Results published in the Clinical Therapeutics
- 02 Feb 2017 New trial record